Acute Kidney Injury and Cancer: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes

  • Colm C. MageeEmail author


Acute kidney injury (AKI) is an important complication of cancer and its treatment. Although AKI in the cancer patient is often multifactorial, it is useful to consider its causes under the traditional categories of prerenal, intrarenal, and postrenal. Risk factors which predispose to AKI in the cancer patient include advanced age, pre-existing renal disease, hypovolemia, intrinsic nephrotoxicity of a given chemotherapy drug, and the cumulative dose of nephrotoxic drugs received. As in many areas of medical practice, the development of AKI is generally associated with a poorer overall prognosis. Identification of at-risk patients allows measures to reduce the risk of AKI. Where AKI does occur, early diagnosis and treatment is important—this is most likely to happen when there is close collaboration between oncologists and nephrologists.


Acute kidney injury Cancer Malignancy Nephrotoxicity Tumor lysis syndrome Hemolytic uremic syndrome Hematopoietic cell transplantation 


  1. 1.
    Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol [Internet]. 2005 Jan [cited 2012 Sep 17];16(1):151–61. Available from: Scholar
  2. 2.
    Rosner MH, Perazella MA. Acute kidney injury in patients with cancer. N Engl J Med. 2017;377(5):500–1.PubMedGoogle Scholar
  3. 3.
    Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924–36.PubMedGoogle Scholar
  4. 4.
    Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med [Internet]. 2005 Jan 27 [cited 2016 Sep 10];352(4):373–9. Available from:
  5. 5.
    Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol [Internet]. 2001 Jun [cited 2016 Sep 9];12(6):1164–72. Available from:
  6. 6.
    Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, Ribes D, Faguer S. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115(12):1457–61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol [Internet]. 2012 Oct [cited 2016 Sep 10];7(10):1713–21. Available from:
  8. 8.
    Schlondorff JS, Mendez GP, Rennke HG, Magee CC. Electrolyte abnormalities and progressive renal failure in a cancer patient. Kidney Int [Internet]. 2007 Jun [cited 2012 Sep 17];71(11):1181–4. Available from: Scholar
  9. 9.
    Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int [Internet]. 2003 Jul [cited 2016 Sep 9];64(1):281–9. Available from:
  10. 10.
    Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med [Internet]. 2005 Dec 6 [cited 2016 Sep 9];143(11):777–84. Available from: Scholar
  11. 11.
    Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol [Internet]. 2010 Sep 1 [cited 2016 Sep 9];28(25):3979–86. Available from: Scholar
  12. 12.
    Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer [Internet]. 2004 Jun 15 [cited 2012 Aug 22];100(12):2664–70. Available from:
  13. 13.
    Cho A, Lee JE, Kwon GY, Huh W, Lee HM, Kim YG, Kim DJ, Oh HY, Choi HY. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant. 2011;26(11):3496–501.CrossRefPubMedGoogle Scholar
  14. 14.
    Parikh CR, Schrier RW, Storer B, Diaconescu R, Sorror ML, Maris MB, et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis [Internet]. 2005 Mar [cited 2016 Sep 10];45(3):502–9. Available from: Scholar
  15. 15.
    Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med [Internet]. 2010 Nov 25 [cited 2016 Sep 10];363(22):2091–101. Available from: Scholar
  16. 16.
    Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant [Internet]. 2010 Feb [cited 2016 Sep 10];16(2):157–68. Available from: Scholar
  17. 17.
    Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood [Internet]. 2016 Mar 31 [cited 2016 Sep 10];127(13):1656–65. Available from: Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NephrologyBeaumont HospitalDublinIreland

Personalised recommendations